Find the Right China Pathway for Your Program

China is not a single market-entry decision. It can serve as an execution base, a source of early human evidence, a formal clinical development market, a commercial opportunity, or a source of innovative assets. Start with your objective to find the pathway, requirements, and risks that actually apply to you.

Step 1

What Are You Trying to Achieve?

Choose the objective closest to your program today. This isn't a ranking of options — different goals lead to genuinely different pathways, requirements, and risks.

Step 2

A Few Questions to Refine It

These don't change your objective — they surface the caveats that matter most for your situation.

Your Recommendation

Recommended Pathway

Reference

Compare All Pathways

A side-by-side view, independent of your specific answers above.

Cross-Cutting

Regulatory Gates

Questions that come up regardless of which pathway you choose. General orientation only — not legal or regulatory advice.

Service Partner Shortlist

Find the Right CRO or CDMO

Start with the work package, modality, development stage, and destination regulator—not the company name. Use this shortlist to build an initial vendor list, then qualify the exact facility and project team.

Verified Directory

China Official Resource Directory

Primary regulatory, clinical, diligence, transaction, and market-access resources for working in China. Chinese-language sources are retained where they are the official record.

Independent research initiative. Pathways are based on publicly available regulations, clinical records, company disclosures, and practitioner interviews. Official-directory links prioritize primary government, regulator, registry, exchange, court, and accreditation sources and were verified in July 2026. The CRO/CDMO shortlist is an editorial classification based on publicly documented service scope, operating scale, specialization, and global-development relevance; it is not an official rating, paid listing, or substitute for facility-level diligence. Resources are included for informational purposes and do not constitute endorsement. This content is not legal, regulatory, or investment advice — verify anything program-specific with qualified counsel.

Independent · Non-Profit · Research Initiative